Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960707 | 0.77 | ALDH1A1 (0.35) | KMT2A | |
| SCHEMBL2788610 | 0.74 | KEAP1 (0.59) | KEAP1NFE2L2CHRM3CHRM2CHRM4 | |
| SCHEMBL9960856 | 0.72 | PKM (0.33) | PKM | |
| SCHEMBL9960728 | 0.72 | PKM (0.33) | PKM | |
| SCHEMBL4203042 | 0.72 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM4 | |
| SCHEMBL4213705 | 0.72 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM4 | |
| SCHEMBL4203592 | 0.72 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM4 | |
| SCHEMBL9960826 | 0.71 | LTB4R (0.36) | — | |
| SCHEMBL9960749 | 0.70 | KCNN4 (0.36) | KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL14587261 | 0.69 | KEAP1 (0.56) | KEAP1NFE2L2CHRM3CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | claimed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | KEAP1 634/4885NFE2L2 158/4885CHRM3 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.